Literature DB >> 19175799

Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Yoh Matsumoto1, Il-Kwon Park, Keiko Hiraki, Shin Ohtani, Kuniko Kohyama.   

Abstract

Accumulating evidence suggests that T cells and autoantibodies reactive with myelin oligodendrocyte glycoprotein (MOG) play a critical role in the pathogenesis of multiple sclerosis (MS). In the present study, we have tried to elucidate the pathomechanisms of development and progression of the disease by analysing T cells and autoantibodies in MOG-induced rat experimental autoimmune encephalomyelitis (EAE), which exhibits various clinical subtypes mimicking MS. Analysis using overlapping peptides revealed that encephalitogenic epitopes resided in peptide 7 (P7, residue 91-108) and P8 (residue 103-125) of MOG. Immunization with MOGP7 and MOGP8 induced relapsing-remitting or secondary progressive EAE. T cells taken from MOG-immunized and MOGP7-immunized rats responded to MOG and MOGP7 and sera from MOG-immunized rats reacted to MOG and MOGP1. Significant epitope spreading was not observed at either T-cell or antibody levels. Interestingly, sera from MOGP7-immunized rats with clinical signs did not react to MOG and MOG peptides throughout the observation period, suggesting that disease development and relapse in MOGP7-induced EAE occur without autoantibodies. However, MOGP7 immunization with adoptive transfer of anti-MOG antibodies aggravated the clinical course of EAE only slightly. Analysis of antibodies against conformational epitope (cme) suggests that anti-MOG(cme) may play a role in the pathogenicity of anti-MOG antibodies. Collectively, these findings demonstrated that relapse of a certain type of MOG-induced EAE occurs without autoantibodies but that autoantibodies may play a role in disease progression. Relapses and the progression of MS-mimicking EAE are differently immunoregulated so immunotherapy should be designed appropriately on the basis of precise information.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19175799      PMCID: PMC2753944          DOI: 10.1111/j.1365-2567.2008.02955.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  49 in total

Review 1.  Multiple sclerosis.

Authors:  J H Noseworthy; C Lucchinetti; M Rodriguez; B G Weinshenker
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis.

Authors:  G Ristori; F Giubilei; D Giunti; A Perna; C Gasperini; C Buttinelli; M Salvetti; A Uccelli
Journal:  J Neuroimmunol       Date:  2000-10-02       Impact factor: 3.478

3.  Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis.

Authors:  M V Tejada-Simon; Y C Zang; D Yang; J Hong; S Li; R A Singh; E Van den Berg-Loonen; J M Killian; V M Rivera; J Z Zhang
Journal:  Int Immunol       Date:  2000-12       Impact factor: 4.823

4.  Differential effects of decoy chemokine (7ND) gene therapy on acute, biphasic and chronic autoimmune encephalomyelitis: implication for pathomechanisms of lesion formation.

Authors:  Il-Kwon Park; Keiko Hiraki; Kuniko Kohyama; Yoh Matsumoto
Journal:  J Neuroimmunol       Date:  2007-12-26       Impact factor: 3.478

5.  Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.

Authors:  C L Vanderlugt; K L Neville; K M Nikcevich; T N Eagar; J A Bluestone; S D Miller
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

6.  MHC class II-regulated central nervous system autoaggression and T cell responses in peripheral lymphoid tissues are dissociated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.

Authors:  R Weissert; K L de Graaf; M K Storch; S Barth; C Linington; H Lassmann; T Olsson
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

8.  The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study.

Authors:  Niklas K U Koehler; Claude P Genain; Barbara Giesser; Stephen L Hauser
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

9.  Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination.

Authors:  Hans-Christian von Büdingen; Stephen L Hauser; Antje Fuhrmann; Cameron B Nabavi; Joy I Lee; Claude P Genain
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat.

Authors:  Z Ahmed; D Gveric; G Pryce; D Baker; J P Leonard; M L Cuzner; L T Diemel
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

View more
  4 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

2.  Prenatal Dexamethasone Exposure Increases the Susceptibility to Autoimmunity in Offspring Rats by Epigenetic Programing of Glucocorticoid Receptor.

Authors:  Yanhong Sun; Xiaoyan Wan; Juan Ouyang; Renfeng Xie; Xueping Wang; Peisong Chen
Journal:  Biomed Res Int       Date:  2016-12-18       Impact factor: 3.411

Review 3.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

Review 4.  Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.

Authors:  Katja Schmitz; Gerd Geisslinger; Irmgard Tegeder
Journal:  Int J Mol Sci       Date:  2017-09-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.